Emerging Targets for Therapeutic Development in Diabetes and Its Complications: The RAGE Signaling Pathway
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Types 1 and 2 diabetes are on the rise worldwide. Although the treatment of hyperglycemia has benefited from recent advances, aggressive efforts to maintain euglycemia may be fraught with risk, especially in older subjects or in subjects vulnerable to hypoglycemic unawareness. Hence, strategies to prevent and treat the complications of hyperglycemia are essential. In this review we summarize recent updates on the biology of the receptor for advanced glycation endproducts (RAGE) in the pathogenesis of both micro‐ and macrovascular complications of diabetes, insights from the study of mouse models of obesity and diabetic complications, and from associative studies in human subjects. The study of the mechanisms and consequences of the interaction of the RAGE cytoplasmic domain with the formin, mDia1, in RAGE signal transduction, will be discussed. Lastly, we review the "state‐of‐the‐art" on RAGE‐directed therapeutics. Tackling RAGE/mDia1 may identify a novel class of therapeutics preventing diabetes and its complications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Advanced Glycation End Products: Sparking the Development of Diabetic Vascular Injury
Goldin, A., Beckman, J. A., Schmidt, A. M., & Creager, M. A. (2006) · Circulation · doi:10.1161/circulationaha.106.621854 · Cited by 2,261 · cited 1×
“In a prediabetic and diabetic environment in humans and animals, AGEs can crosslink with both intracellular and extracellular proteins as well as bind to their central cell surface receptor RAGE (receptor for advanced glycation endproducts) in circulation and in a variety of tissues.(8) AGE-RAGE interactions activate…”
BackgroundSelf-citationRAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012
Self-citationBlockade of RAGE-amphoterin signalling suppresses tumour growth and metastases
Taguchi, A., Blood, D. C., del Toro, G., Canet, A., Lee, D. C., Qu, W., Tanji, N., Lu, Y., Lalla, E., Fu, C., et al. (2000) · Nature · doi:10.1038/35012626 · Cited by 1,217
Self-citationDeane, R., Singh, I., Sagare, A. P., Bell, R. D., Ross, N. T., LaRue, B., Love, R., Perry, S., Paquette, N., Deane, R. J., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58642 · Cited by 619 · cited 1×
“Small-molecule antagonists of RAGE were shown to block immune activation in islet allografts(76) in mice and Alzheimer’s disease pathology in mouse models.(77) Nanocarriers bearing RAGE siRNAs were tested in animal models of myocardial infarction.”
BackgroundSoro-Paavonen, A., Watson, A. M. D., Li, J., Paavonen, K., Koitka, A., Calkin, A. C., Barit, D., Coughlan, M. T., Drew, B. G., Lancaster, G. I., et al. (2008) · Diabetes · doi:10.2337/db07-1808 · Cited by 407 · cited 1×
“Furthermore, diabetic Ager null/Apoe null mice demonstrate reduced atherosclerotic plaque lesion size as compared to diabetic Apoe null controls.(41) Further, in distinct studies, deletion of Ager in Apoe null mice rendered diabetic with streptozotocin resulted in reduced lesional macrophage, T cell, and”
BackgroundAdvanced glycation endproducts and its receptor for advanced glycation endproducts in obesity
Gaens, K. H., Stehouwer, C. D., & Schalkwijk, C. G. (2013) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32835aea13 · Cited by 166 · cited 4×
“Finally, in most studies reporting measurements of sRAGEs, the investigators did not report the prevalence of AGER SNPs known to affect levels of the sRAGEs.”
BackgroundInfluential
Cited by
Update on the pathogenesis and treatment of skeletal fragility in type 2 diabetes mellitus
Khosla, S., Samakkarnthai, P., Monroe, D. G., & Farr, J. N. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00555-5 · Cited by 260
Zhou, M., Zhang, Y., Shi, L., Li, L., Zhang, D., Gong, Z., & Wu, Q. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107282 · Cited by 253
The Role of Dietary Advanced Glycation End Products in Metabolic Dysfunction
Sergi, D., Boulestin, H., Campbell, F. M., & Williams, L. M. (2021) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201900934 · Cited by 194
Accelerated osteocyte senescence and skeletal fragility in mice with type 2 diabetes
Eckhardt, B. A., Rowsey, J. L., Thicke, B. S., Fraser, D. G., O’Grady, K. L., Bondar, O. P., Hines, J. M., Singh, R. J., Thoreson, A. R., Rakshit, K., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.135236 · Cited by 130
Kidney, heart and brain: three organs targeted by ageing and glycation
Frimat, M., Daroux, M., Litke, R., Nevière, R., Tessier, F. J., & Boulanger, E. (2017) · Clinical Science · doi:10.1042/cs20160823 · Cited by 88
Metadata
- Authors
- Litwinoff, E., Hurtado del Pozo, C., Ramasamy, R., & Schmidt, A.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2015-06-25
- Volume
- 98
- Issue
- 2
- Pages
- 135-144
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W1582822824
- Cited by
- 103
- References
- 6
- FWCI
- 5.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emerging Targets for Therapeutic Development in Diabetes and Its Complications: The RAGE Signaling Pathway. https://app.cochat.ai/papers/10.1002/cpt.148
- The paper
- Litwinoff, E., Hurtado del Pozo, C., Ramasamy, R., & Schmidt, A. (2015). Emerging Targets for Therapeutic Development in Diabetes and Its Complications: The RAGE Signaling Pathway. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.148
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.